Research Clinical Trials and Studies

1. Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
   Protocol: TRC-PAD
   Sponsor: ATRI

2. An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Repeat Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia
   Protocol: ABP-19000
   Sponsor: Aeon BioPharma

3. Extension Study of ABP-19000 to Evaluate Safety and Efficacy of Repeat Treatments of ABP-450 in Cervical Dystonia
   Protocol: ABP-19002 EXT.
   Sponsor: Aeon BioPharma

4. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 2)
   Protocol: 15T-MC-AACI
   Sponsor: Lilly

5. A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
   Protocol: 15T-MC-AACM
   Sponsor: Lilly

6. A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
Protocol:CVN424-201
Sponsor: Cerevance

7. A 2-Part, Open Label, Adaptive, Single and/or Multiple Oral Dose, Safety, Tolerability, and Food Effect Trial of CVL-751 in Subjects With Parkinson's Disease.
Protocol: CVL-751-PD-002
Sponsor: Cerevel

8. A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Study of the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy in Levodopa-Treated Subjects With Parkinson's Disease With Motor Fluctuation.
Protocol: CVL-751-PD-003
Sponsor: Cervel

9. A study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants with Preclinical Alzheimer’s Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid.
Protocol: AHEAD 3-45
Sponsor: EISAI/ATRI

10. A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease.
Protocol: BN42358
Sponsor: Genentech

11. Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson's Disease.
Protocol: NLY01-PD-1
Sponsor: Neuraly

12. A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless).
Protocol: ND0612-317
Sponsor: NeuroDerm

13. New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study - A Study to Improve Precision in Amyloid PET Coverage and Patient Car.
Protocol: New IDEAS study
Sponsor: New IDEAS study

14. A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 With Immediate-Release Carbidopa-Levodopa in Parkinson's Disease Patients With Motor Fluctuations.
Protocol: IPX203-B16-02
Sponsor: Impax

15. An Open-label Extension Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease Patients With Motor Fluctuations.
Protocol: IPX203-B16-03 EXT.
Sponsor: Impax

16. A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease.
Protocol: T3D959-202
Sponsor: T3d Therapeutics

17. Safety and Efficacy of Allopregnanolone (Allo) as a Regenerative Therapeutic for Alzheimer's Disease: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Clinical Trial.
Protocol: Allo-20-001
Sponsor: Regen-Brain

18. A Double-blind, Randomized, Placebo-controlled, Parallel, Study to Assess the Efficacy and Safety of XW10172 MR for the Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease.
Protocol: XW10172-104
Sponsor: XW Pharma

19. A Diagnostic Test for Dementia with Lewy Bodies.
Protocol: SYN-D Study
Sponsor: CND Life Sciences

20. Teva Start: Real-World Utilization of Deutetrabenazine Initiated by a 4-week Patient Titration Kit.
Protocol: TV50717-CNS-40189
Sponsor: Teva Pharmaceuticals

If you have questions about our research studies, leave your contact information and our team will contact you.

You do not need medical insurance to participate.

Role: Dr. Rodríguez and Dr. Benes collaborate together as principal investigators for these clinical studies.

NEUROLOGY ONE
ADVANCED CENTER FOR NEUROSCIENCE & BRAIN WELLNESS